Radiotherapy of Grade III Gliomas: Identification of Clinical Prognostic Factors for Local Tumor Control and Survival

DIRK RADES1, JASPAR WITTELER1 and STEVEN E. SCHILD2

1Department of Radiation Oncology, University of Lübeck, Lübeck, Germany; 2Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, U.S.A.

Abstract. Background/Aim: The prognoses of patients with grade III gliomas require improvement, which may be achieved with personalized care. We aimed to identify prognostic factors to facilitate the process of treatment personalization. Patients and Methods: Eight factors were analyzed for local tumor control and survival in 44 patients irradiated for grade III glioma. These factors included location and size of glioma, number of glioma sites, performance status, gender, age, neurosurgical intervention and chemotherapy. Results: In the Cox regression analyses, frontal location (risk ratio=4.41, p=0.048) and unifocal glioma (risk ratio=4.65, p=0.034) were associated with improved local control, and unifocal glioma with improved survival (risk ratio=6.12, p=0.033). In addition, trends for better survival were observed for frontal location (p=0.093), age ≤49 years (p=0.070), upfront resection (p=0.099) and chemotherapy (p=0.066) on univariate analyses. Conclusion: Independent predictors of local tumor control and survival were identified that can be helpful for personalizing treatment and designing clinical trials.

The World Health Organization (WHO) classification of gliomas includes four grades (I-IV), and grade III gliomas are considered high-grade tumors (1, 2). Grade III gliomas are rare and account for about 3% of primary brain tumors and tumors of the central nervous system (3-5). Patients with grade III gliomas often have comparably poor prognoses, and the tumors can also negatively impact patients’ quality of life (5). When compared to low-grade gliomas (grade I or II) and glioblastomas (grade IV), fewer studies have focused on diagnosis, treatment and prognosis of grade III gliomas (5). Moreover, most studies investigating high-grade gliomas combine grade III and IV tumors, although the prognoses are quite different, and are dominated by the significantly more common grade-IV tumors (5, 6). Therefore, the present study was conducted including only patients with grade III gliomas. Its major goal is the identification of independent prognostic factors for local tumor control and survival that can lead to better personalization of individual treatment programs and likely to an improvement of the patients’ prognoses.

Patients and Methods

The data of 44 patients receiving radiotherapy for grade III glioma were retrospectively analyzed for local tumor control and survival. The study had received its approval from the local Ethics Committee at the University of Lübeck (reference=15-355A). Radiotherapy was performed after biopsy only (n=13, 30%) or after resection (n=31, 70%). Gross tumor resection was achieved in 7 patients, and macroscopically incomplete resection in 22 patients; the extent of resection remained unclear in 2 patients. The median total dose of radiotherapy following neurosurgical intervention was 59.4 Gy (54.0-60.0 Gy), and the median dose per fraction 1.8 Gy (1.8-2.0 Gy). Thirty-three patients (75%) received additional chemotherapy, most frequently with temozolomide (TMZ) alone (23 patients). Moreover, three patients received PC-chemotherapy including procarbazine and lomustine (CCNU) alone, six patients sequential administration of both TMZ and PC, and one patient nimustine (ACNU) alone.

Eight factors were analyzed for a potential prognostic impact with respect to local tumor control and survival, including main location of the glioma (frontal vs. other locations), number of glioma sites (unifocal vs. multifocal), cumulative maximum diameter of the glioma (<35 vs. ≥35 mm, according to Fang et al. (5)), Karnofsky performance score (KPS) (≤80 vs. >80%), gender, age at start of radiotherapy (<49 vs. ≥49 years, according to Curran et al. (7)), upfront neurosurgical intervention (biopsy vs. resection), and chemotherapy in addition to radiotherapy (no vs. yes). Frontal location (n=22) included frontal location only (n=14), fronto-temporal location (n=5), fronto-parietal location (n=2) and frontal...
plus paraventricular location (n=1). The distributions of the eight factors are shown in Table I.

Time to local tumor progression and time to death were referenced from the last day of irradiation. Univariate analyses for both endpoints were performed with the Kaplan-Meier method plus log-rank test. \( p \)-Values <0.10 indicated a trend, and \( p \)-values <0.05 demonstrated significance. The significant factors were subsequently included in a multivariate Cox regression analysis.

**Results**

Data for local tumor control were available for 35 patients. In these patients, the median time to local failure was 44 months, and local control rates at 1, 2 and 3 years were 73%, 68% and 57%, respectively. On univariate analysis of local tumor control, frontal location \( (p=0.020) \) and unifocal glioma \( (p=0.002) \) were significantly associated with improved outcomes (Table II). In the Cox regression analysis, both main location of the glioma (risk ratio=4.41, 95% CI=1.01-31.10, \( p=0.048 \)) and number of glioma sites (risk ratio=4.65, 95% CI=1.13-17.98, \( p=0.034 \)) remained significant.

In the entire cohort of 44 patients, median survival following radiotherapy was 132 months, and survival rates at 1, 2 and 3 years were 93%, 83% and 68%, respectively. On univariate analysis of survival, unifocal glioma \( (p=0.009) \) were significantly associated with improved outcomes (Table III). In addition, trends were observed for frontal location \( (p=0.093) \), age \( \leq 49 \) years \( (p=0.070) \), resection prior to irradiation \( (p=0.099) \) and additional chemotherapy \( (p=0.066) \). In the Cox regression analysis, number of glioma sites (risk ratio=6.12, 95% confidence interval=1.17-28.68, \( p=0.033 \)) maintained significance.

**Discussion**

In total, gliomas account for approximately 30% of primary brain tumors (8). Of all gliomas, only about 10% are grade III tumors (3-5). These patients were reported to have poor prognoses. Because of the rarity of grade III gliomas, very few studies have focused specifically on this subgroup of gliomas. The outcomes of patients with malignant diseases may be improved with personalized treatment programs, ideally, considering the individual prognostic factors for each patient. Survival is an important outcome that should be considered when selecting an optimal personalized treatment. In general, patients with poor estimated survival should receive short and little burdensome treatments, whereas tumor control and late sequelae require higher attention when aiming to treat long-term survivors. These strategies were particularly described for patients with metastatic cancer, but can also be important for patients with grade III gliomas (9-12).

This study was conducted to identify prognostic factors for survival and local tumor control in patients receiving radiotherapy after neurosurgical intervention for grade III glioma. In addition to survival, local tumor control is important, since local progression is often the life-limiting factor in glioma patients whose tumors do not metastasize. In the present study, frontal location and unifocal glioma showed significant associations with better local tumor control in the multivariate analysis. Improved survival was independently associated with unifocal glioma; trends were observed on univariate analyses for frontal location, age \( \leq 49 \) years, upfront resection, and addition of chemotherapy.

Some of these factors were previously identified as associated with outcomes after treatment for grade III glioma, which demonstrates consistency regarding our present findings. However, when interpreting these findings, one should consider the limitations of this study including its retrospective nature and small sample size. In 2009, Park et al. reported a retrospective series of 133 patients with grade III gliomas, who received radiotherapy (mean dose=59.4Gy) with (50%) or without (50%) PCV-chemotherapy (procarbazine, CCNU, vincristine) (13). In the multivariate analysis, age \( \leq 50 \) years \( (p=0.002) \), Eastern Cooperative Oncology Group performance score 0-1 representing a better performance status \( (p=0.003) \), and complete tumor resection

### Table I. Factors evaluated for local control and survival.

| Factor                        | Number of patients (%) |
|-------------------------------|------------------------|
| Main location of glioma       |                        |
| Frontal                       | 22 (50)                |
| Other                         | 22 (50)                |
| Number of glioma sites         |                        |
| Unifocal                      | 35 (80)                |
| Multifocal                    | 7 (16)                 |
| Unknown                       | 2 (5)                  |
| Cumulative maximum diameter   |                        |
| <35 mm                        | 12 (27)                |
| ≥35 mm                        | 18 (41)                |
| Karnofsky performance score   |                        |
| <80%                          | 20 (45)                |
| >80%                          | 21 (48)                |
| Gender                        |                        |
| Female                        | 22 (50)                |
| Male                          | 22 (50)                |
| Age at start of radiotherapy  |                        |
| ≥49 Years                     | 25 (57)                |
| >49 Years                     | 19 (43)                |
| Upfront neurosurgical intervention |                  |
| Biopsy                        | 13 (30)                |
| Resection                     | 31 (70)                |
| Additional chemotherapy       |                        |
| No                            | 11 (25)                |
| Yes                           | 33 (75)                |
In the multivariate analysis, age ≤49 years was significantly associated with better survival, and age <50 years (p=0.002) were significantly associated with progression-free survival (local tumor control, p<0.001) (17). These data support the present finding that unifocal glioma is a significant prognostic factor for treatment outcomes in patients with grade III gliomas.

In summary, independent predictors of local tumor control and survival were identified for patients with grade III gliomas including a new factor, namely number of glioma sites. These prognostic factors that can be helpful for personalizing treatments and designing future clinical trials.

**Conflict of Interest**

The Authors report no conflicts of interest regarding this study.
Authors’ Contributions

D.R., J.W. and S.E.S. participated in the design of the study. J.W. collected the data that were analyzed by all Authors. D.R. and S.E.S. drafted the article, which was reviewed and finally approved by all Authors.

References

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007 WHO classification of tumours of the central nervous system diagnosed in the United States in 2012-2016. Neuro Oncol 21(suppl 5): v1-v100, 2019. PMID: 31759594. DOI: 10.1093/neuonc/noz150

2. Ostrem QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C and Barnholtz-Sloan JS: CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro Oncol 16: 841-864, 2018. PMID: 30504399. DOI: 10.1093/annonc/mdy458

3. Fang JH, Lin DD, Deng XY, Li DD, Sheng HS, Lin J, Zhang N and Yin B: Epidemiological trends, relative survival, and prognosis risk factors of WHO Grade III gliomas: A population-based study. Cancer Med 8: 3286-3295, 2019. PMID: 31016895. DOI: 10.1002/cam4.2164

4. Stupp R, Brada M, van den Bent MJ, Tonn JC and Penthoudakis G; ESMO Guidelines Working Group: High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(suppl 3): iii93-101, 2014. PMID: 24782454. DOI: 10.1093/annonc/mdu050

5. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE and Nelson DF: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85: 704-710, 1993. PMID: 8478956. DOI: 10.1093/jnci/85.9.704

6. Forst DA, Nahed BV, Loeffler JS and Batchelor TT: Low-grade gliomas. Oncologist 19: 403-413, 2014. PMID: 24664484. DOI: 10.1634/theoncologist.2013-0345

7. Rades D, Dziggel L and Schild SE: A specific survival score for patients receiving local therapy for single brain metastasis from a gynecological malignancy. In Vivo 32: 825-828, 2018. PMID: 29936465. DOI: 10.21873/inivo.11314

8. Rades D, Sehmisch L, Hansen HC, Dziggel L, Janssen S and Schild SE: Comparison of diagnosis-specific survival scores for patients with cerebral metastases from malignant melanoma including the new WBRT-30-MM. Anticancer Res 39: 1501-1505, 2019. PMID: 30842188. DOI: 10.21873/anticancerres.13268

9. Rades D, Dziggel L, Manig L, Janssen S, Khoa MT, Duong VN, Khien VH and Schild SE: Predicting survival after whole-brain irradiation for cerebral metastases in patients with cancer of the bladder. In Vivo 32: 633-636, 2018. PMID: 29695570. DOI: 10.21873/inivo.11285

10. Rades D, Sondermann L, Motisi L, Janssen S, Cacicedo J and Schild SE: Prognostic factors and a survival score in patients irradiated for metastatic epidural spinal cord compression from urothelial carcinoma of the bladder. Anticancer Res 38: 6841-6846, 2018. PMID: 30504399. DOI: 10.21873/anticancerres.13058

11. Park CK, Lee SH, Han JH, Kim CY, Kim DW, Paek SH, Kim DG, Heo DS, Kim H and Jung HW: Recursive partitioning analysis of prognostic factors in WHO grade III glioma patients treated with radiotherapy or radiotherapy plus chemotherapy. BMC Cancer 9: 450, 2009. PMID: 20017960. DOI: 10.1186/1471-2407-9-450

12. Mayer A, Schwanbeck C, Sommer C, Stockinger M, Giese A, Renovanz M, Vaupel P and Schmidberger H: Adjuvant temozolomide-based chemoradiotherapy versus radiotherapy alone in patients with WHO III astrocytoma: The Mainz experience. Strahlenther Onkol 191: 665-671, 2015. PMID: 26025143. DOI: 10.1007/s00066-015-0855-x.

13. Fujii Y, Muragaki Y, Maruyama T, Nitta M, Saito T, Ikuta S, Iseki H, Hongo K and Kawamata T: Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI. J Neurosurg 129: 1-9, 2018. PMID: 28885120. DOI: 10.3171/2017.3.JNS162383

14. Witteler J, Kjaer TW, Tvilsted S, Schild SE and Rades D: Seizures prior to radiotherapy of gliomas: Prevalence, risk factors and survival prognosis. Anticancer Res 40: 3961-3965, 2020. PMID: 32620638. DOI: 10.21873/anticancerres.14388

15. Dietterle J, Wende T, Wilhelmy F, Eisenloffel C, Jähne K, Taubenheim S, Arlt F and Meixensberger J: The prognostic value of peri-operative neurological performance in glioblastoma patients. Acta Neurochir (Wien) 162: 417-425, 2020. PMID: 31736002. DOI: 10.1007/s00701-019-04136-4